Nexalin Technology (NXL) announces the publication of a landmark study in the Journal of Affective Disorders demonstrating the potential efficacy of its proprietary DIFS technology. The research highlights the potential of DIFS to deliver meaningful reductions in systolic and diastolic blood pressure in patients with major depressive disorder, MDD, while offering a safe and non-invasive approach to addressing systemic health challenges.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXL:
Questions or Comments about the article? Write to editor@tipranks.com